← Leaderboards
Wolfgang W Scholz
Avanir Pharmaceuticals
$5,224,945
Attributed
$5,492,778
Total exposure
4
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.1M · FY2005–12$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
Funding mix
By agency
NIH$5,492,778 · 4
By mechanism
U01$2,058,872 · 1
R44$1,978,841 · 1
R42$1,104,717 · 1
R43$350,348 · 1
Top collaborators
- Philip O. Livingston1 shared
Others in their field
Top investigators on “Scale Up”
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Eric S Lander · Whitehead Institute For Biomedical Res$494,464,719
- Richard K. Wilson · Washington University$429,146,711
- Charles Mattias Mountain · Association Of Universities For Research In Astronomy, Inc.$404,701,805
- Richard A Gibbs · Baylor College Of Medicine$358,687,223
- David Heimbrook · Leidos Biomedical Research, Inc.$350,022,833
Research focus
Scale UpSarcomaNeuroblastomaNeoplastic CellProductionResponseGangliosidesLocal TherapyMelanomaNeoplasm MetastasisOperative Surgical ProceduresOverexpressionPublic Health RelevanceRadiation TherapyCell SurfaceConjugate VaccinesImmunoglobulin GImmunoglobulin MAntigensMalignant NeoplasmsMemorial Sloan-Kettering Cancer CenterMicrometastasisAntibodiesSmall Business Technology Transfer Research
Grant awards (7)
Impact of Vaccination against GM2, GD2 and GD3 on Disease Free Survival in Resect$854,905
R44 · FY2012 · CA · contact PI
Impact of Vaccination against GM2, GD2 and GD3 on Disease Free Survival in Resect$973,936
R44 · FY2011 · CA · contact PI
Characterization of human antibodies to sialyl-Lewis A (sLeA) derived from patien$569,051
R42 · FY2011 · CA · contact PI
Characterization of human antibodies to sialyl-Lewis A (sLeA) derived from patien$535,666
R42 · FY2010 · CA
Impact of Vaccination against GM2, GD2 and GD3 on Disease Free Survival in Resect$150,000
R44 · FY2010 · CA · contact PI
Development of Human Monoclonal Antibody for Treatment of Anthrax Exposure$2,058,872
U01 · FY2006 · AI · contact PI
Human Antibodies for Exposure/Protection from Anthrax$350,348
R43 · FY2005 · AI